Alto Neuroscience shares are trading lower after the company announced topline results from a Phase 2b trial evaluating ALTO-100 as a treatment for major depressed disorder did not meet its primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
Alto Neuroscience shares fell after the company announced that its Phase 2b trial for ALTO-100, a treatment for major depressive disorder, did not meet its primary endpoint.
October 23, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Alto Neuroscience's stock is negatively impacted as the Phase 2b trial for their drug ALTO-100 did not meet its primary endpoint, leading to a decrease in share price.
The failure to meet the primary endpoint in a clinical trial is a significant setback for a biotech company, often leading to a decrease in investor confidence and a drop in stock price. This is particularly true for Alto Neuroscience as the trial was for a major depressive disorder treatment, a key area of focus for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100